Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

G. Perera, M. Ranola, D. B. Rowe, G. M. Halliday, N. Dzamko*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)
6 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker'. Together they form a unique fingerprint.

Medicine & Life Sciences